Adage Capital Partners
UBX

Adage Capital Partners’s Unity Biotechnology UBX Stock Holding History

Adage Capital Partners’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-250,000
Closed -$685K – 997
2022
Q4 		$685K Sell
250,000
-100,000
-29% -$291K ﹤0.01% 854
2022
Q3 		$1.38M Buy
+350,000
New +$2.21M ﹤0.01% 875

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners's UBX Position: Q1 2023 in Review

Adage Capital Partners sold out of Unity Biotechnology (UBX) in Q1 2023, closing a stake of 250,000 shares — an estimated $685K sold.

Adage Capital Partners first reported a position in UBX in Q3 2022 and held it in 2 quarters. The position peaked at $1.38M in Q3 2022. 46 funds tracked by Wall St. Rank hold UBX as of Q1 2023.

  • Adage Capital Partners reported no remaining Unity Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Adage Capital Partners sold 250,000 Unity Biotechnology shares in Q1 2023, an estimated $685K.
  • Adage Capital Partners first reported a position in Unity Biotechnology in Q3 2022 and held it in 2 quarters.
  • Adage Capital Partners's Unity Biotechnology position peaked at $1.38M in Q3 2022.
  • 46 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2023.

Based on Adage Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.